1. Home
  2. BNR vs RVPH Comparison

BNR vs RVPH Comparison

Compare BNR & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNR
  • RVPH
  • Stock Information
  • Founded
  • BNR 2014
  • RVPH 2006
  • Country
  • BNR China
  • RVPH United States
  • Employees
  • BNR N/A
  • RVPH N/A
  • Industry
  • BNR Medical Specialities
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNR Health Care
  • RVPH Health Care
  • Exchange
  • BNR Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • BNR 38.3M
  • RVPH 26.6M
  • IPO Year
  • BNR 2020
  • RVPH N/A
  • Fundamental
  • Price
  • BNR $6.47
  • RVPH $0.46
  • Analyst Decision
  • BNR
  • RVPH Strong Buy
  • Analyst Count
  • BNR 0
  • RVPH 5
  • Target Price
  • BNR N/A
  • RVPH $9.00
  • AVG Volume (30 Days)
  • BNR 53.8K
  • RVPH 3.2M
  • Earning Date
  • BNR 08-21-2025
  • RVPH 08-13-2025
  • Dividend Yield
  • BNR N/A
  • RVPH N/A
  • EPS Growth
  • BNR N/A
  • RVPH N/A
  • EPS
  • BNR N/A
  • RVPH N/A
  • Revenue
  • BNR $72,112,038.00
  • RVPH N/A
  • Revenue This Year
  • BNR $136.32
  • RVPH N/A
  • Revenue Next Year
  • BNR N/A
  • RVPH N/A
  • P/E Ratio
  • BNR N/A
  • RVPH N/A
  • Revenue Growth
  • BNR 0.53
  • RVPH N/A
  • 52 Week Low
  • BNR $2.18
  • RVPH $0.30
  • 52 Week High
  • BNR $9.48
  • RVPH $4.28
  • Technical
  • Relative Strength Index (RSI)
  • BNR 60.79
  • RVPH 46.82
  • Support Level
  • BNR $5.81
  • RVPH $0.44
  • Resistance Level
  • BNR $9.48
  • RVPH $0.53
  • Average True Range (ATR)
  • BNR 0.90
  • RVPH 0.04
  • MACD
  • BNR 0.12
  • RVPH 0.02
  • Stochastic Oscillator
  • BNR 45.86
  • RVPH 56.07

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: